EA021527B1 - Соединения для уменьшения продукции бета-амилоида - Google Patents

Соединения для уменьшения продукции бета-амилоида Download PDF

Info

Publication number
EA021527B1
EA021527B1 EA201270824A EA201270824A EA021527B1 EA 021527 B1 EA021527 B1 EA 021527B1 EA 201270824 A EA201270824 A EA 201270824A EA 201270824 A EA201270824 A EA 201270824A EA 021527 B1 EA021527 B1 EA 021527B1
Authority
EA
Eurasian Patent Office
Prior art keywords
aseno
methyl
metheno
cyclopenta
mmol
Prior art date
Application number
EA201270824A
Other languages
English (en)
Russian (ru)
Other versions
EA201270824A1 (ru
Inventor
Кеннет М. Бой
Джейсон М. Гернон
Джон Е. Макор
Лорин А. Томпсон III
Юн-Цзинь У
Юньхуй Чзан
Original Assignee
Бристол-Майерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майерс Сквибб Компани filed Critical Бристол-Майерс Сквибб Компани
Publication of EA201270824A1 publication Critical patent/EA201270824A1/ru
Publication of EA021527B1 publication Critical patent/EA021527B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201270824A 2010-07-15 2011-07-12 Соединения для уменьшения продукции бета-амилоида EA021527B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36442510P 2010-07-15 2010-07-15
PCT/US2011/043628 WO2012009309A1 (en) 2010-07-15 2011-07-12 Compounds for the reduction of beta-amyloid production

Publications (2)

Publication Number Publication Date
EA201270824A1 EA201270824A1 (ru) 2013-04-30
EA021527B1 true EA021527B1 (ru) 2015-07-30

Family

ID=44511486

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270824A EA021527B1 (ru) 2010-07-15 2011-07-12 Соединения для уменьшения продукции бета-амилоида

Country Status (18)

Country Link
US (1) US8637523B2 (enExample)
EP (1) EP2593461B1 (enExample)
JP (1) JP5755739B2 (enExample)
KR (1) KR20130041944A (enExample)
CN (1) CN102971325B (enExample)
AR (1) AR082241A1 (enExample)
AU (1) AU2011279412B2 (enExample)
BR (1) BR112013000920A2 (enExample)
CA (1) CA2805294A1 (enExample)
CO (1) CO6670589A2 (enExample)
EA (1) EA021527B1 (enExample)
IL (1) IL224202A (enExample)
MX (1) MX2013000514A (enExample)
NZ (1) NZ606950A (enExample)
SG (1) SG186392A1 (enExample)
TW (1) TW201206946A (enExample)
WO (1) WO2012009309A1 (enExample)
ZA (1) ZA201301178B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0696663B2 (ja) 1986-08-04 1994-11-30 東レ株式会社 樹脂組成物
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PE20190736A1 (es) 2012-06-13 2019-05-23 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR101473081B1 (ko) 2013-01-25 2014-12-16 영남대학교 산학협력단 고리형 2-다이아조-1,3-다이카보닐 화합물을 출발물질로 하는 고리형 베타-엔아미노아마이드 유도체 및 우라실 유도체의 합성방법
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
WO2014180524A1 (en) * 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
WO2014195322A1 (en) 2013-06-04 2014-12-11 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
NO3004079T3 (enExample) 2013-06-04 2018-06-16
CN105308037B (zh) 2013-06-04 2017-09-19 阿克图拉姆生命科学股份公司 三唑化合物及其作为γ分泌酶调节剂的用途
US9833454B2 (en) 2014-04-02 2017-12-05 Bristol-Myers Squibb Company Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
CA2999931A1 (en) 2015-09-29 2017-04-06 Bayer Pharma Aktiengesellschaft Novel macrocyclic sulfondiimine compounds
JP6888000B2 (ja) 2015-10-08 2021-06-16 バイエル ファーマ アクチエンゲゼルシャフト 新規な修飾された大環状化合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
WO2020151682A1 (zh) * 2019-01-23 2020-07-30 成都先导药物开发股份有限公司 一种大环类免疫调节剂
US12331038B2 (en) 2019-01-29 2025-06-17 Shandong Xuanzhu Pharma Co., Ltd. Hexone glucokinase inhibitor and use thereof
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087127A1 (en) * 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Modulators for amyloid beta

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101365703B (zh) * 2005-11-16 2013-11-06 S*Bio私人有限公司 杂烷基连接的嘧啶衍生物
US7932261B2 (en) * 2006-02-06 2011-04-26 Janssen Pharmaceutica Nv Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
ITMI20061513A1 (it) 2006-07-31 2008-02-01 Poli Costruzione Materiali Trazione Spa Unita' frenante compatta a disco per veicoli su rotaia
AU2008333865A1 (en) * 2007-12-06 2009-06-11 Schering Corporation Gamma secretase modulators
US8426595B2 (en) * 2007-12-11 2013-04-23 Xianhai Huang Gamma secretase modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087127A1 (en) * 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Modulators for amyloid beta

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CONDE S.: "[beta]-amyloid peptide as a target for treatment of Alzheimer's disease", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 12, no. 4, 1 January 2002 (2002-01-01), pages 503-512, XP002276299, ISSN: 1354-3776, DOI: 10.1517/13543776.12.4.503, the whole document *

Also Published As

Publication number Publication date
AR082241A1 (es) 2012-11-21
KR20130041944A (ko) 2013-04-25
CO6670589A2 (es) 2013-05-15
EP2593461A1 (en) 2013-05-22
NZ606950A (en) 2014-08-29
IL224202A (en) 2016-04-21
CN102971325A (zh) 2013-03-13
ZA201301178B (en) 2014-07-30
SG186392A1 (en) 2013-02-28
MX2013000514A (es) 2013-02-27
US8637523B2 (en) 2014-01-28
AU2011279412A1 (en) 2013-03-07
WO2012009309A1 (en) 2012-01-19
JP5755739B2 (ja) 2015-07-29
BR112013000920A2 (pt) 2016-05-17
TW201206946A (en) 2012-02-16
EP2593461B1 (en) 2016-08-17
US20120184565A1 (en) 2012-07-19
JP2013531040A (ja) 2013-08-01
CA2805294A1 (en) 2012-01-19
CN102971325B (zh) 2016-01-20
EA201270824A1 (ru) 2013-04-30
AU2011279412B2 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
EA021527B1 (ru) Соединения для уменьшения продукции бета-амилоида
TWI468402B (zh) 降低β-類澱粉生成之化合物
JP6453507B2 (ja) Mcl−1タンパク質を阻害する化合物
JP5638007B2 (ja) ベータ−アミロイド産生の減少のための二環式化合物
EP2744499B1 (en) Inhibitors of the renal outer medullary potassium channel
US11787803B2 (en) Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
CN102827170A (zh) 治疗活性组合物和它们的使用方法
EA017937B1 (ru) ПРОИЗВОДНЫЕ 3-АМИНОПИРРОЛО[3,4-c]ПИРАЗОЛ-5(1H,4H,6H)-КАРБАЛЬДЕГИДА В КАЧЕСТВЕ ИНГИБИТОРОВ РКС
MX2013008219A (es) Benzoazepinas sustituidas como moduladores de receptores tipo toll.
CA3063934A1 (en) Kinase inhibitors and uses thereof
EP3582780A1 (en) Amino pyrimidine compounds useful as ssao inhibitors
CA3066909A1 (en) Substituted bridged diazepane derivatives and use thereof as task-1 and task-3 inhibitors
EP3212618B1 (en) Inhibitors of the renal outer medullary potassium channel
EP4056571A1 (en) Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof
WO2019031990A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19
EP2668168B1 (en) COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION
JP2017521440A (ja) 腎髄質外層カリウムチャンネルの阻害剤
RU2739489C2 (ru) Новые гетероциклические соединения как ингибиторы CDK8/19
WO2025024329A2 (en) Compounds, compositions, and methods
HK1164732B (en) Compounds for the reduction of beta-amyloid production
WO2015138689A1 (en) Fused morpholinopyrimidines and methods of use thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU